Tradestie Institutional Equity Comparison Engine

BHC vs AVDL โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

AVDL Overall Edge

AVDL Captures Institutional Edge (2โ€“2 Pillars ยท 6โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Avadel Pharmaceuticals plc Ordinary Share (AVDL) driven by superior Growth & Margin, Momentum & Technical while BHC counters with relative strength in Valuation, Options & Structure. Fundamentally, BHC trades at 1.9x Forward P/E with 27.2% operating margin (+9.7% YoY revenue) versus AVDL at 28.8x Forward P/E and 2.5% operating margin (+54.9% YoY). In options structure, BHC sits in BREAKOUT (100th %ile IV; Dealer Gamma Walls on Pro) against AVDL sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner BHC
BHC 1.9x vs AVDL 28.8x Fwd P/E
Growth & Margin Winner AVDL
Op Margin 27.2% vs 2.5% ยท YoY +9.7% vs +54.9%
Momentum & Technical Winner AVDL
1Y +35.9% vs +138.1% ยท 52W Pos 83% vs 89%
Options & Structure Winner BHC
BREAKOUT (100th %ile IV) vs UNCLASSIFIED (<1st %ile IV)
BHC NYSE
Bausch Health Companies Inc
Pharmaceutical Preparations
$8.22
-3.97% 1D
Market Cap $3.2B
1M Return +26.66%
1Y Return +35.87%
Forward P/E 1.9x
Unified AI Score
44.1 / 100 HOLD
Tech 32.0 Fund 47.0 Flow 70.0 Mom 41.1
AVDL NASDAQ
Avadel Pharmaceuticals plc Ordinary Share
Pharmaceutical Preparations
$21.64
+0.05% 1D
Market Cap $2.1B
1M Return +0.65%
1Y Return +138.06%
Forward P/E 28.8x
Unified AI Score
62.9 / 100 BUY
Tech 75.0 Fund 60.0 Flow 50.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: BHC +35.87% AVDL +138.06% Spread: +6.82 pp (BHC Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
BHC TTM Op. Margin: 27.2% AVDL TTM Op. Margin: 2.5%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BHC vs AVDL. Trailing 12-month operating profitability (BHC 27.2% vs AVDL 2.5%) and valuation multiples (BHC 1.9x vs AVDL 28.8x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: BHC (4) vs AVDL (6)
Institutional Metric BHC AVDL Criterion Row Winner
Market Capitalization Scale $3.2B $2.1B Larger Scale BHC
Trailing P/E Ratio Valuation 2.0x 16.8x Lower Multiple BHC
Forward P/E Ratio Valuation 1.9x 28.8x Lower Multiple BHC
Revenue Growth (YoY) Growth +9.7% +54.9% Higher Growth AVDL
Operating Margin (TTM) Profitability 27.2% 2.5% Higher Margin BHC
Net Profit Margin Profitability -7.6% -0.1% Higher Margin AVDL
Return on Equity (ROE) Capital Efficiency -11040.0% -0.3% Higher ROE AVDL
52-Week Range Position Momentum 83% ($4โ€“$9) 89% ($6โ€“$24) Stronger Trend AVDL
Beta / 30D Volatility Risk Regime 0.96ฮฒ ยท 111% Vol 0.14ฮฒ ยท 2% Vol Lower Realized Risk AVDL
Unified Institutional Score Composite Signal 44.1 / 100 (HOLD) 62.9 / 100 (BUY) Higher Composite AVDL

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full BHC vs AVDL Buy Guide
BHC BREAKOUT
78d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 100th %ile
IV Regime Extreme (>80th %ile)
Live BHC Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
AVDL UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile <1st %ile
IV Regime Compressed (<25th %ile)
Live AVDL Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither BHC nor AVDL registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.